Sex Specific Analysis Of Cardiovascular Function

This book gathers together contributions from internationally renowned authors in the field of cardiovascular systems and provides crucial insight into the importance of sex- and gender-concepts during the analysis of patient data. This innovative title is the first to offer the elements necessary to consider sex-related properties in both clinical and basic studies regarding the heart and circulation on multiscale levels (i.e. molecular, cellular, electrophysiologically, neuroendocrine, immunoregulatory, organ, allometric, and modeling). Observed differences at (ultra)cellular and organ level are quantified, with focus on clinical relevance and implications for diagnosis and patient management. Since the cardiovascular system is of vital importance for all tissues, Sex-Specific Analysis of Cardiovascular Function is an essential source of information for clinicians, biologists, and biomedical investigators. The wide spectrum of differences described in this book will also act as an eye-opener and serve as a handbook for students, teachers, scientists and practitioners.

Scientific evidence from both preclinical, and clinical studies indicates that male and female patients with cardiovascular disease (CVD) exhibit different clinical, epidemiological, and pathological characteristics, with sexually dimorphic biological factors exhibiting a significant influence in the development of CVD and therapeutic responses. Sexually dimorphic physiology that contributes to sex differences in cardiovascular therapeutic responses may include; immune responses, cardio-renal health, the blood-brain barrier, coronary atherosclerosis pathology, complications of COVID-19 infections, and the interplay between psychological factors and sedentarism. Furthermore, current knowledge indicates the role of hormonal regulation has a significant impact in sex-specific differences across the clinical cardiology field. The National Institute of Health (NIH) previously adopted a policy to encourage researchers to consider sex as a biological variable (SABV) as well as Sex and Gender Equity in Research (SAGER). In order to promote sexual dimorphic cardiovascular therapeutic development, we have organized this special topic “Sex Differences and Cardiovascular Therapeutics” to provide a scientific forum for cardiovascular scientists and clinicians to present their newest findings in characterizing sex differences in cardiovascular therapeutics. Potential areas of research within this collection may include, but are not limited to: 1) Different outcomes and responses to drug treatment in cardiovascular disease between male and female. 2) Mechanisms of sexual dimorphic response and outcomes related to drug treatment of cardiovascular disease. 3) Sex hormones and their receptors in cardiovascular function in animal studies and clinical therapeutic applications. 4) Gender affirming hormone therapy and cardiovascular function. 5) Regulatory guidance for cardiovascular therapeutics in relation to sex-specific differences.

Sex Differences in Cardiovascular Physiology and Pathophysiology is a comprehensive look into the often overlooked and underappreciated fundamental sex differences between men and women and how those differences affect the cardiovascular system. It covers cardiovascular function, anatomy, cell signaling and the development of pathology. With contributions from world-renowned research investigators, this up-to-date reference compiles critical knowledge on cardiovascular sex differences, providing researchers and clinicians with a better understanding of the diagnosis, prevention and treatment of cardiovascular diseases in both men and women. Identifies the fundamental sex differences in the physiology and pathophysiology of the cardiovascular system Describes cell signaling pathways involved in sex-associated cardiovascular function and diseases Puts the sex differences in cardiovascular diseases in the forefront to improve cardiovascular prognoses

During the last years the understanding for the aetiology of cardiomyopathies could be greatly improved. A great deal of information has accumulated in the field of inherited metabolic diseases, which provides a new basis for our understanding of many heart muscle problems and their corresponding clinical disease entities. This book is meant to give the reader a comprehensive overview of the cardiological manifestations of inborn errors of metabolism. Latest information, such as cardiomyopathy in Fabry disease or in patients with CDG-syndrome is included. It should be helpful, not only to cardiologists, paediatricians, internists and general practicioners, but also to all those interested in a better understanding of the metabolic basis of clinical disease entities.

The number of women participating in clinical trials has increased during the last two decades, but women are still underrepresented in clinical trials in general. Some of the overall increase can be attributed to the greater number of women-only trials (of therapies for diseases that affect only women). Even when women are included in clinical trials, the results are often not analyzed separately by sex. On August 30, 2011, the Institute of Medicine (IOM) Board on Population Health and Public Health Practice hosted the workshop Sex-Specific Reporting of Scientific Research. The workshop explored the need for sex-specific reporting of scientific results; potential barriers and unintended consequences of sex-specific reporting of scientific results; experiences of journals that have implemented sex-specific requirements, including the challenges and benefits of such editorial policies; and steps to facilitate the reporting of sex-specific results. Presenters and participants included current and former editors of scientific journals, researchers, and scientists and policymakers from government, industry, and nonprofit organizations. Presentations and discussions highlighted the importance to both women and men of having sex-specific data, the problems with sample size and financial constraints for conducting the research, the appropriateness of sex-specific analyses, and the limitations of journal policies to change experimental designs. Sex-Specific Reporting of Scientific Research summarizes the presentations and discussions by the expert panelists during the IOM workshop. The workshop's first session focused on why sex-specific reporting is important. Panelists highlighted historical and current events that have hindered or helped to advance the study of women. In the next session, panelists in academe discussed the challenges of collecting, analyzing, and reporting sex-specific data from the researcher's perspective. That was followed by two panels of leading journal editors who shared their experiences in developing and implementing editorial policies and the implications of sex-specific reporting policies for journals.

It's obvious why only men develop prostate cancer and why only women get ovarian cancer. But it is not obvious why women are more likely to recover language ability after a stroke than men or why women are more apt to develop autoimmune diseases such as lupus. Sex differences in health throughout the lifespan have been documented. Exploring the Biological Contributions to Human Health begins to snap the pieces of the puzzle into place so that this knowledge can be used to improve health for both sexes. From behavior and cognition to metabolism and response to chemicals and infectious organisms, this book explores the health impact of sex (being male or female, according to reproductive organs and chromosomes) and gender (one's sense of self as male or female in society). Exploring the Biological Contributions to Human Health discusses basic biochemical differences in the cells of males and females and health variability between the sexes from conception throughout life. The book identifies key research needs and opportunities and addresses barriers to research. Exploring the Biological Contributions to Human Health will be important to health policy makers, basic, applied, and clinical researchers, educators, providers, and journalists-while being very accessible to interested lay readers.

The book provides a reference for years to come, written by world-renowned expert investigators studying sex differences, the role of sex hormones, the systems biology of sex, and the genetic contribution of sex chromosomes to metabolic homeostasis and diseases. In this volume, leaders of the pharmaceutical industry present their views on sex-specific drug discovery. Many of the authors presented at the Keystone Symposium on “Sex and gender factors affecting metabolic homeostasis, diabetes and obesity” to be held in March 2017 in Lake Tahoe, CA. This book will generate new knowledge and ideas on the importance of gender biology and medicine from a molecular standpoint to the population level and to provide the methods to study them. It is intended to be a catalyst leading to gender-specific treatments of metabolic diseases. There are fundamental aspects of metabolic homeostasis that are regulated differently in males and females, and influence both the development of diabetes and obesity and the response to pharmacological intervention. Still, most preclinical researchers avoid studying female rodents due to the added complexity of research plans. The consequence is a generation of data that risks being relevant to only half of the population. This is a timely moment to publish a book on sex differences in diseases as NIH leadership has asked scientists to consider sex as a biological variable in preclinical research, to ensure that women get the same benefit of medical research as men.

Caffeine in Food and Dietary Supplements is the summary of a workshop convened by the Institute of Medicine in August 2013 to review the available science on safe levels of caffeine consumption in foods, beverages, and dietary supplements and to identify data gaps. Scientists with expertise in food safety, nutrition, pharmacology, psychology, toxicology, and related disciplines; medical professionals with pediatric and adult patient experience in cardiology, neurology, and psychiatry; public health professionals; food industry representatives; regulatory experts; and consumer advocates discussed the safety of caffeine in food and dietary supplements, including, but not limited to, caffeinated beverage products, and identified data gaps. Caffeine, a central nervous stimulant, is arguably the most frequently ingested pharmacologically active substance in the world. Occurring naturally in more than 60 plants, including coffee beans, tea leaves, cola nuts and cocoa pods, caffeine has been part of innumerable cultures for centuries. But the caffeine-in-food landscape is changing. There are an array of new caffeine-containing energy products, from waffles to sunflower seeds, jelly beans to syrup, even bottled water, entering the marketplace. Years of scientific research have shown that moderate consumption by healthy adults of products containing naturally-occurring caffeine is not associated with adverse health effects. The changing caffeine landscape raises concerns about safety and whether any of these new products might be targeting populations not normally associated with caffeine consumption, namely children and adolescents, and whether caffeine poses a greater health risk to those populations than it does for healthy adults. This report delineates vulnerable populations who may be at risk from caffeine exposure; describes caffeine exposure and risk of cardiovascular and other health effects on vulnerable populations, including additive effects with other ingredients and effects related to pre-existing conditions; explores safe caffeine exposure levels for general and vulnerable populations; and identifies data gaps on caffeine stimulant effects.